Cold sores traced back to kissing in Bronze Age by Cambridge research
Scientists say a strain of herpes arose during vast migrations of people 5,000 years ago. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 28, 2022 Category: Consumer Health News Source Type: news
Modern herpes variants may be linked to bronze age kissing, study finds
Virus may have received a boost from rise of kissing that came with westward migrations 4,500 years agoThe herpes variants that cause modern cold sores became widespread in the wake of bronze age migrations, and may have received a boost from the practice of kissing that came with it, researchers say.Scientists in Cambridge analysed the first ancient DNA specimens of herpes simplex virus and found that one variant overtook all others about 4,500 years ago, setting the course for its dominance today.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 27, 2022 Category: Science Authors: Ian Sample Science editor Tags: Infectious diseases Genetics Archaeology Anthropology Biology Science Source Type: news
What are Potential Problems with Placental Abnormalities?
Discussion
“The placenta is a unique organ that sits at the interface of, and facilitates nearly all interactions between, maternal and fetal physiology. It is the sole source of oxygen and nutrition for the fetus, and provides a protective barrier against external insults. The placenta is also a highly adaptable organ that is capable of showing a wide range of pathological changes in response to various maternal and fetal factors and stressors.” The placenta has 3 layers: the amnion (fetal side), the chorion, and decidua (maternal side). In addition to making observations about the maternal and fetal sides, co...
Source: PediatricEducation.org - June 27, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Do Cold Sores Mean You Have an STD?
Title: Do Cold Sores Mean You Have an STD?Category: Diseases and ConditionsCreated: 9/8/2020 12:00:00 AMLast Editorial Review: 3/11/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - March 11, 2022 Category: Dermatology Source Type: news
STI: Four warning signs of an infection with the herpes simplex virus – it has 'no cure'
GENITAL herpes is considered a "common" sexually transmitted infection . Triggered by the herpes simplex virus, here are the warning signs of the contagious condition. (Source: Daily Express - Health)
Source: Daily Express - Health - February 22, 2022 Category: Consumer Health News Source Type: news
What Kills Cold Sores Naturally?
Title: What Kills Cold Sores Naturally?Category: Diseases and ConditionsCreated: 2/18/2022 12:00:00 AMLast Editorial Review: 2/18/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - February 18, 2022 Category: Dermatology Source Type: news
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - January 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
UofL researchers reveal how oral bacteria suppress protection against viral growth
Bacteria that cause periodontal disease reduce oral defense and increase viral growth By Betty Coffman LOUISVILLE, Ky. – Researchers from the University of Louisville School of Dentistry and their colleagues have discovered details of how proteins produced by oral epithelial cells protect humans against viruses entering the body through the mouth. They also found that oral bacteria can suppress the activity of the se cells, increasing vulnerability to infection. A family of proteins known as interferon lambdas produced by epithelial cells in the mouth serve to protect humans from viral infection, but...
Source: Dental Technology Blog - January 6, 2022 Category: Dentistry Source Type: news
How Does Toothpaste Get Rid of Cold Sores Overnight?
Title: How Does Toothpaste Get Rid of Cold Sores Overnight?Category: Health and LivingCreated: 12/21/2021 12:00:00 AMLast Editorial Review: 12/21/2021 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - December 21, 2021 Category: Dermatology Source Type: news
NIDCR's Winter 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Winter 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NIDCR News
Science Advances
NIDCR News
NIDCR Major Announcement: Save the Date!
Mark your calendar for Tuesday, December 21, at 1pm for a major webcast announcement from NIDCR. Look for log-in instructions, coming in a separate NIDCR email next week.
Jennifer Webster-Cyriaque Joins NIDCR as Deputy Director
NIDCR welcomed Jennifer Webster-...
Source: NIDCR Science News - December 8, 2021 Category: Dentistry Source Type: news
